MRTFB and hepatocellular carcinoma: We employed polymer-based nanoparticles for the in vivo delivery of an siRNA targeting both MKL1 and 2, a combination of MKL1 and MKL2 siRNAs and MKL1 siRNA alone to established HCC xenografts.